LDLR and familial hypercholesterolemia: Circulating PCSK9 binds to the LDL receptor and diverts it to lysosomes for degradation, thereby leading to decreased LDL receptor abundance at the hepatocyte cell surface, decreased LDL clearance, and hypercholesterolemia.